Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/node/24582

Instructional Course Director(s)

Todd Morgan, MD

University of Michigan

Instructional Course Faculty(s)

Leonard Gomella, MD,FACS

Professor And Chair

Thomas Jefferson University

Heather Cheng, MD, PhD

University of Washington

There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. PARP inhibition), Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in greater than 10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer.

Learning Objectives:

Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening

Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results

Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.